Terns Pharmaceuticals (TERN) Operating Income (2020 - 2022)
Terns Pharmaceuticals (TERN) has disclosed Operating Income for 4 consecutive years, with -$24.1 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, Operating Income fell 42.96% year-over-year to -$24.1 million, compared with a TTM value of -$91.4 million through Dec 2023, down 47.29%, and an annual FY2023 reading of -$102.6 million, down 65.34% over the prior year.
- Operating Income was -$24.1 million for Q4 2023 at Terns Pharmaceuticals, up from -$33.2 million in the prior quarter.
- Across five years, Operating Income topped out at -$8.7 million in Q3 2020 and bottomed at -$33.2 million in Q3 2023.
- Average Operating Income over 4 years is -$14.7 million, with a median of -$13.6 million recorded in 2021.
- The sharpest move saw Operating Income decreased 3.98% in 2022, then crashed 91.9% in 2023.
- Year by year, Operating Income stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then crashed by 42.96% to -$24.1 million in 2023.
- Business Quant data shows Operating Income for TERN at -$24.1 million in Q4 2023, -$33.2 million in Q3 2023, and -$16.8 million in Q4 2022.